SO
CBIO

STRS Ohio’s Crescent Biopharma CBIO Stock Holding History

STRS Ohio’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-18
Closed -$11K – 1900
2016
Q4 		$10K Sell
18
-135
-88% -$84.2K ﹤0.01% 1884
2016
Q3 		$109K Sell
153
-6
-4% -$4.59K ﹤0.01% 1670
2016
Q2 		$115K Buy
+159
New +$110K ﹤0.01% 1666

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

STRS Ohio's CBIO Position: Q1 2017 in Review

STRS Ohio sold out of Crescent Biopharma (CBIO) in Q1 2017, closing a stake of 18 shares — an estimated $11K sold.

STRS Ohio first reported a position in CBIO in Q2 2016 and held it in 3 quarters. The position peaked at $115K in Q2 2016. 43 funds tracked by Wall St. Rank hold CBIO as of Q1 2017.

  • STRS Ohio reported no remaining Crescent Biopharma position as of Q1 2017 after selling out during the quarter.
  • STRS Ohio sold 18 Crescent Biopharma shares in Q1 2017, an estimated $11K.
  • STRS Ohio first reported a position in Crescent Biopharma in Q2 2016 and held it in 3 quarters.
  • STRS Ohio's Crescent Biopharma position peaked at $115K in Q2 2016.
  • 43 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2017.

Based on STRS Ohio's 13F filing for Q1 2017, filed 26 Apr 2017.